Jazz Pharmaceuticals
JAZZ
JAZZ
407 hedge funds and large institutions have $5B invested in Jazz Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 124 increasing their positions, 171 reducing their positions, and 85 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
407
Holders Change
-39
Holders Change %
-8.74%
% of All Funds
8.99%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
51
Increased
124
Reduced
171
Closed
85
Calls
$18.3M
Puts
$27.2M
Net Calls
-$8.94M
Net Calls Change
-$2.8M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$50.3M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$38.7M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$32.1M |
| 4 |
Holocene Advisors
New York
|
+$29.8M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$15.7M |
Top Sellers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$44.7M |
| 2 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$43.1M |
| 3 |
Bank of New York Mellon
New York
|
-$41M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$35.7M |
| 5 |
D.E. Shaw & Co
New York
|
-$25.5M |
